PARP抑制剂治疗BRCA1/2突变转移性乳腺癌的研究进展

doi:10.11904/j.issn.1002-3070.2021.02.016

Abstract

CLC Number:

R737.9

HU Yang, ZHANG Qingyuan. Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer[J]. Journal of Practical Oncology, 2021, 35(2): 184-187.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/10.11904/j.issn.1002-3070.2021.02.016

http://journal09.magtechjournal.com/Jwk3_syzlxzz/EN/Y2021/V35/I2/184

1 Sulaiman A,Wang L.Bridging the divide:preclinical research discrepancies between triple-negative breast cancer cell lines and patient tumors[J].Oncotarget,2017,8(68):113269-113281.
2 Lewin R,Sulkes A,Shochat T,et al.Oncotype-DX recurrence score distribution in breast cancer patients with BRCA1/2 mutations[J].Breast Cancer Res Treat,2016,157(3):511-516.
3 Akihiro O,Shinichi Y.Current status of poly(ADP-ribose)polymerase inhibitors and future directions[J].Onco Targets Ther,2017,10:5195-5208.
4 D'Andrea AD.Mechanisms of PARP inhibitor sensitivity and resistance[J].DNA Repair,2018,71:172-176.
5 Brown JS,Ocarrigan B,Jackson SP,et al.Targeting DNA repair in cancer:beyond PARP inhibitors[J].Cancer Discov,2017,7(1):20-37.
6 Evers B,Helleday T,Jonkers J.Targeting homologous recombination repair defects in cancer[J].Trends Pharmacol Sci,2010,31(8):372-380.
7 朱志超,白煜,卢绪章,等.PARP抑制剂olaparib对急性髓系白血病细胞HL-60抑制作用研究[J].实用肿瘤学杂,2019,33(6):481-485.
8 Eustermann S,Wu WF,Langelier MF,et al.Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1[J].Mol Cell,2015,60(5):742-754.
9 Vos MD,Schreiber V,Dantzer F.The diverse roles and clinical relevance of PARPs in DNA damage repair:Current state of the art[J].Biochem Pharmacol,2012,84(2):137-146.
10 Keung MYT,Wu Y,Vadgama JV.PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers[J].J Clin Med,2019,8(4):435.
11 Ashworth A,Lord CJ.Synthetic lethal therapies for cancer:what's next after PARP inhibitors?[J].Nat Rev Clin Oncol,2018,15(9):564-576.
12 Lord CJ,Ashworth A.PARP inhibitors:synthetic lethality in the clinic[J].Science,2017,355(6330):1152-1158.
13 Caulfield SE,Davis CC,Byers KF.Olaparib:a novel therapy for metastatic breast cancer in patients with a BRCA1/2 mutation[J].J Adv Pract Oncol,2019,10(2):167-174.
14 Gelmon K,Fasching P,Couch F,et al.Real-world clinical effectiveness and safety of olaparib monotherapy in HER2-negative gBRCA-mutated metastatic breast cancer:Phase IIIb LUCY interim analysis[J].J Clin Oncol,2020,38:1087.
15 Shen Y,Rehman FL,Feng Y,et al.BMN 673,a novel and highly potent PARP1/2 inhibitor for the treatment of human cancers with DNA repair deficiency[J].Clin Cancer Res,2013,19(18):5003-5015.
16 Turner NC,Telli ML,Rugo HS,et al.A phase II study of talazoparib after platinum or cytotoxic nonplatinum regimens in patients with advanced breast cancer and germline BRCA1/2 mutations(ABRAZO)[J].Clin Cancer Res,2019,25(9):2717-2724.
17 Ettl J,Quek RGW,Lee KH,et al.Quality of life with talazoparib versus physician's choice of chemotherapy in patients with advanced breast cancer and germline BRCA1/2 mutation:patient-reported outcomes from the EMBRACA phase III trial[J].Ann Oncol,2018,29(9):1939-1947.
18 Hoy SM.Talazoparib:first global approval[J].Drugs,2018,78(18):1939-1946.
19 Mirza MR,Monk BJ,Herrstedt J,et al.Niraparib maintenance therapy in platinum-sensitive,recurrent ovarian cancer[J].N Engl J Med,2016,375(22):2154-2164.
20 USA National Library of Medicine.A feasibility study of niraparib for advanced,BRCA1-like,HER2-negative breast cancer patients[https://clinicaltrials.gov/ct2/show/NCT02826512].2016.
21 McCann KE,Hurvitz SA.Advances in the use of PARP inhibitor therapy for breast cancer[J].Drugs Context,2018,7:212540.
22 Han HS,Diéras V,Robson M,et al.Veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in patients with BRCA1/2 locally recurrent/metastatic breast cancer:randomized phase II study[J].Ann Oncol,2018,29(1):154-161.
23 Diéras V,Han HS,Kanfman B,et al.LBA9 Phase 3 study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer[J].Ann Oncol,2019,30:857-858.
24 Patsouris A,Vicier C,Campion L,et al.An open-label,phase II study of rucaparib,a PARP inhibitor,in HER2-metastatic breast cancer patients with high genomic loss of heterozygosity[J].J Clin Oncol,2017,35:1117.
25 Faraoni I,Graziani G.Role of BRCA mutations in cancer treatment with poly(ADP-ribose)polymerase(PARP)inhibitors[J].Cancers,2018,10(12):487.
26 Drew Y,Ledermann J,Hall G,et al.Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose)polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer[J].Br J Cancer,2016,114(7):723-730.
27 Wilson RH,Evans TJ,Middleton MR,et al.A phase I study of intravenous and oral rucaparib in combination with chemotherapy in patients with advanced solid tumours[J].Br J Cancer,2017,116(7):884-892.
28 Keung MYT,Wu Y,Vadgama JV.PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers[J].J Clin Med,2019,8(4):435.

[1]	YANG Min, ZHANG Jiaoyan, Duan Dan, XU Binghe. Bibliometrics and visual analysis of breast cancer caregivers [J]. Journal of Practical Oncology, 2021, 35(2): 110-116.
[2]	LIU Ke, WANG Shenglin. Research on the correlation between X-ray imaging and molecular types and histological grade of breast invasive ductal carcinoma [J]. Journal of Practical Oncology, 2021, 35(2): 148-153.
[3]	NIU Ming, YU Ge. Gankyrin promotes tumor proliferation,metastasis and cancer stem cell characteristic in breast cancer [J]. Journal of Practical Oncology, 2020, 34(6): 518-523.
[4]	LIU Hong, LU Hailing, CAI Li. Advances in imaging prediction of prognosis and neoadjuvant chemotherapy response in breast cancer patients [J]. Journal of Practical Oncology, 2020, 34(6): 535-539.
[5]	YUAN Yao, ZHOU Xianli. Research progress on the correlation between ultrasound features and axillary lymph node metastasis in breast cancer [J]. Journal of Practical Oncology, 2020, 34(6): 576-580.
[6]	HAN Jing, PU Yan, LIU Huibin. Effects of SKA1 on cell proliferation and apoptosis of renal cell carcinoma and its molecular mechanism [J]. Journal of Practical Oncology, 2020, 34(5): 404-411.
[7]	ZHAO Yunxia, NIU Bo. Effect of lncRNA NBAT1 on proliferation of breast cancer cells by regulating the molecular axis of miR-3664-5p/Caspase 9 [J]. Journal of Practical Oncology, 2020, 34(1): 24-29.
[8]	HU Lin, SHEN Jia. Growth differentiation factor 15 plays a role in predicting and monitoring the cardiotoxicity of epirubicin/cyclophosphamide-docetaxel-trastuzumab in the treatment of patients with HER-2 positive breast cancer [J]. Journal of Practical Oncology, 2019, 33(4): 340-345.
[9]	MA Yan, HE Hong, WANG Sainan. Clinical study of docetaxel in the treatment of metastatic breast cancer in different age groups [J]. Journal of Practical Oncology, 2019, 33(4): 352-356.
[10]	WANG Xiaoya,XIAO Bin,LIAO Yang,TANG Rongzhi,SUN Zhaohui,LI Linhai. Expression of CXCR family proteins in different subtypes of breast cancer and their clinical prognosis [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(3): 206-210.
[11]	CHEN Yanbo, KONG Dejia, ZHANG Jinfeng, MA Zhigang. Correlation between CYP2D6 gene polymorphism and tamoxifen metabolism in breast cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 110-114.
[12]	SUN Jianghong, HAO Mingzhu, JIANG Dan, GUO Fei, LI Xiaomei. FFDM differential diagnosis of mastitis,benign hyperplasia and breast cancer [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 139-141.
[13]	MA Zhijie, WANG Fan, ZHAO Yashuang. Analysis of life quality and influencing factors in breast cancer patients with chemotherapy [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(2): 149-154.
[14]	BAI Yuxian, MA Zhongjuan, SU Yingling, MU Anguo, XIE Rui. Research on methylation of FHIT,hMLH1,p16,RAR-beta,Reprimo and TIMP3 genes in gastric cancer patients [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 8-13.
[15]	MA Zhingying, SHANG Naijian, CAI Miaotian, SHEN Yang, JIANG Zhiyun. Correlation between HER-2 receptor of progesterone and estrogen receptor-positive breast cancer and mammography imaging & clinicopathological features [J]. PRACTICAL ONCOLOGY JOURNAL, 2019, 33(1): 47-51.

Research progress of PARP inhibitors in the treatment of BRCA1/2 mutation metastatic breast cancer

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments